RespiRx is a drug-device combination product that delivers nicotine replacement therapy through an inhaler. Image credit: Josep Suria / Shutterstock. Qnovia has received clearance from the US Food and ...

BISMARCK, N.D. (KFYR) - The pharmaceutical company Qnovia announced that the FDA approved its experimental nicotine inhaler for trial in the U.S. The inhaler, RespiRx, is marketed as a smoking ...

Qnovia has received clearance from the US Food and Drug Administration (FDA) to start a clinical trial for its RespiRX nicotine inhaler as a replacement therapy for smoking. The US-based company ...

Background: Even with effective smoking cessation medications, many smokers are unable to abruptly stop using tobacco. This finding has increased interest in smoking reduction as an interim step ...

In conclusion, NRT (nicotine gum or inhaler) doubled the quit rate compared to placebo and was safe. Active NRT achieved sustained abstinence rates of 20.1% at 4 months and 18.7% at 12 months ...

NEW YORK -- CDC reports teen smoking and other tobacco use dropped to lowest level in 25 years. 24/7 coverage of breaking news and live events ...

Read: Florida’s six constitutional amendments on the November ballot, explained For the first time ever, the CDC also reports nicotine pouches are now the second most commonly used product among ...